Abstract 4484
Hematopoietic stem cell transplantation (HSCT) is the treatment for an increasing number of inherited diseases. Graft rejection and acute Graft Versus Host Disease (GVHD) are known to ...be the two major complications of this procedure. A high frequency of graft rejection is observed particularly in patients with inflammatory conditions associated with congenital metabolic diseases, IFN-gR1 deficiency, familial hemophagocytic lymphohistiocytosis. GVHD results from immunological attack on target recipient organs (skin, liver and gut) by donor allogeneic T cells that are transferred along with the allograft. A better understanding of the patients' inflammatory environment in the course of HSCT may allow for the establishment of predictive markers for the occurrence of engraftment or GVHD and the improvement of conditioning regimens and post-transplant immunosuppressive therapy.
All pediatric patients treated in the Department of Immuno-Hematology at the Necker Hospital who received allogeneic HSCT after full intensity conditioning regimen for nonmalignant disorders including inherited immunodeficiencies, metabolic diseases or hemoglobinopathies are eligible for inclusion.
Plasma samples are collected before conditioning (day-15), at the time of transplant (day 0), at day+15 and day+30 post-HSCT.
Validated markers of GVHD (Elafin, Reg3α, and ST2) as well as pro-inflammatory, anti-inflammatory, and angiogenic cytokines were analyzed, respectively, using sequential enzyme-linked immunosorbent assays and Luminex technology, which enables the determination of large numbers of cytokines in very small amounts of childrens’ plasma. Engraftment was assessed on the presence of full donor chimerism, GVHD upon clinical, biological and histopathological data.
From April 2011 to March 2012, 15 patients were included (8 males and 7 females with an age ranging from 4 months to 9 years). Five patients presented with severe combined immunodeficiencies, three with chronic granulomatous disease, five with metabolic diseases (three Hurler and two osteopetrosis), one with congenital aplastic anemia and one with sickle cell diseaseConditioning regimen consisted of Busulfan/Fludarabin/ATG for ten patients, Busulfan/Fludarabin/Thiotepa/ATG for four patients and Busulfan/Cyclophosphamid/ATG in one. Donors were matched unrelated (n=6), 4 matched related (n=4), haplo-identical (n=4), and with intrafamilial mismatched donor (n=1). Acute graft rejection was observed in 2 of 15 patients and sustained engraftment in 13 of 15. Acute GVHD was observed in 6 of 15 patient occurring between day+10 and day+45 grade 1 (n=1), grade 3 (n=3) and grade 4 (n=2).
At day+30, we found significantly higher plasma concentrations of IFNγ, TNFα, ST2, and VEGF in patients with GVHD as compared to patients without GVHD. TNFα was the only cytokine for which the plasma concentrations was already significantly higher at day+15 in patients with GVHD versus patients without GVHD. No statistically significant differences in plasma concentrations of IL-4, IL-6, TGFβ, IL-7, IL-8, IL-12, IL-13 and IL-17 were observed.
The cytokine that appeared to differentiate patients with GVHD and patients without GVHD the most was IFN-α2 which had plasma concentrations that were consistently and significantly higher in patients without GVHD as compared to patients with GVHD from day-15 to day+15.
These results confirm the Th1 associated profile of acute GVHD and the importance of endothelial dysfunction in GVHD, as suggested by increased concentrations of ST2 and VEGF in patients with GVHD. The potential forIFN-α2 as a predictive marker of GVHD in our population needs further confirmation through additional inclusions. A larger population is also needed to determine if a specific cytokine milieu is associated with other common HSCT complications seen in our population such as graft rejection and vascular complications such as sinusoidal obstructive syndrome of the liver and pulmonary arterial hypertension.
No relevant conflicts of interest to declare.
In studies aimed at further characterizing the cellular immunodeficiency of the Wiskott-Aldrich syndrome (WAS), we found that T lymphocytes from WAS patients display abnormal chemotaxis in response ...to the T-cell chemoattractant stromal cell–derived factor (SDF)-1. The Wiskott- Aldrich syndrome protein (WASP), together with the Rho family GTPase Cdc42, control stimulus-induced actin cytoskeleton rearrangements that are involved in cell motility. Because WASP is an effector of Cdc42, we further studied how Cdc42 and WASP are involved in SDF-1–induced chemotaxis of T lymphocytes. We provide here direct evidence that SDF-1 activates Cdc42. We then specifically investigated the role of the interaction between Cdc42 and WASP in SDF-1–responsive cells. This was achieved by abrogating this interaction with a recombinant polypeptide (TAT-CRIB), comprising the Cdc42/Rac interactive binding (CRIB) domain of WASP and a human immunodeficiency virus–TAT peptide that renders the fusion protein cell-permeant. This TAT-CRIB protein was shown to bind specifically to Cdc42-GTP and to inhibit the chemotactic response of a T-cell line to SDF-1. Altogether, these data demonstrate that Cdc42-WASP interaction is critical for SDF-1–induced chemotaxis of T cells.
CD3 deficiencies Fischer, Alain; de Saint Basile, Geneviève; Le Deist, Françoise
Current opinion in allergy and clinical immunology,
2005-December, Letnik:
5, Številka:
6
Journal Article
The molecular characterization of inherited T-cell immunodeficiencies has contributed to delineating key factors in human T-cell development. This review reports on the recent description of ...deleterious mutations in the genes encoding CD3 subunits expressed at the T-lymphocyte membrane in association with the T-cell receptor.
Homozygous mutations in CD3D and CD3E genes lead to a complete block in T-cell development and thus to an early-onset severe combined immunodeficiency phenotype. Thymic studies have shown that the defect in T-cell development occurs at the transition between 'double-negative' and 'double-positive' thymocytes. These results contrast with the partial T-cell immunodeficiency caused by a deficiency in CD3G.
Two new severe combined immunodeficiency conditions have been reported as a consequence of either CD3D or CD3E deficiency. The distinct phenotype of CD3G deficiency sheds light on the differential roles of CD3 subunits in T-lymphocyte development.
Clinical improvement with disappearance of fever and fatigue occurred within 5 days after the first rituximab injection. ...at 9.5 years of age, she was considered for bone marrow transplantation ...from her healthy, EBV-seropositive, and HLA-identical 20-year-old sister. Laboratory data Before HSCTAge After HSCT(mo postgraft) 2 y 4 y 8 y 9 y 6 mo 12 mo 18 mo 24 mo Eosinophil (N < 500 cells/μL) 8,600 3,500 9,700 1,030 120 130 100 160 IgE (N < 100 IU/mL) >5,000 >5,000 22,000 36,000 2,450 740 439 380 T cell CD4 (N = 650-2,200 cells/μL) 580 397 463 331 528 890 940 830 T cell CD8(N = 370-1,300 cells/μL) 654 142 555 155 2,204 658 845 517 B cell CD19 (N = 390-1,400 cells/μL) 1,426 610 790 1,513 272 1,387 1,555 1,380 NK (N = 130-700 cells/μL) 60 51  211 936 675 240 193 LPT PHA (N > 50 cpm/103)   68 42   35  LPT tetanus (N > 10 cpm/103)   1    33  LPT Candida (N > 10 cpm/103)   0.7 0.55   0.3  LPT HSV (N > 10 cpm/103)   0.8 2.45   27  LPT CMV (N > 10 cpm/103)   0.6    63.5  Table I Eosinophils, IgE levels, and lymphocyte counts before and after HSCT CMV, Cytomegalovirus; cpm, counts per minute; LPT, lymphocytes proliferation test; n, normal values; NK, natural killer; PHA, phytohemagglutinin.
The immunogenetic basis of severe infections caused by bacille Calmette-Guérin vaccine and environmental mycobacteria in humans remains largely unknown. We describe 18 patients from several ...generations of 12 unrelated families who were heterozygous for 1 to 5 overlapping IFNGR1 frameshift small deletions and a wild-type IFNGR1 allele. There were 12 independent mutation events at a single mutation site, defining a small deletion hotspot. Neighbouring sequence analysis favours a small deletion model of slipped mispairing events during replication. The mutant alleles encode cell-surface IFNgamma receptors that lack the intra-cytoplasmic domain, which, through a combination of impaired recycling, abrogated signalling and normal binding to IFNgamma exert a dominant-negative effect. We thus report a hotspot for human IFNGR1 small deletions that confer dominant susceptibility to infections caused by poorly virulent mycobacteria.
Hyper-IgM syndrome (HIGM) is a heterogeneous condition characterized by impaired Ig class-switch recombination (CSR). The molecular defects that have so far been associated with this syndrome - which ...affect the CD40 ligand in HIGM type 1 (HIGM1), CD40 in HIGM3, and activation-induced cytidine deaminase (AID) in HIGM2 - do not account for all cases. We investigated the clinical and immunological characteristics of 15 patients with an unidentified form of HIGM. Although the clinical manifestations were similar to those observed in HIGM2, these patients exhibited a slightly milder HIGM syndrome with residual IgG production. We found that B cell CSR was intrinsically impaired. However, the generation of somatic hypermutations was observed in the variable region of the Ig heavy chain gene, as in control B lymphocytes. In vitro studies showed that the molecular defect responsible for this new HIGM entity (HIGM4) occurs downstream of the AID activity, as the AID gene was induced normally and AID-induced DNA double-strand breaks in the switch mu region of the Ig heavy chain locus were detected during CSR as normal. Thus, HIGM4 is probably the consequence of a selective defect either in a CSR-specific factor of the DNA repair machinery.
The clinical phenotype of interleukin 12 receptor β1 chain (IL-12Rβ1) deficiency and the function of human IL-12 in host defense remain largely unknown, due to the small number of patients reported. ...We now report 41 patients with complete IL-12Rβ1 deficiency from 17 countries. The only opportunistic infections observed, in 34 patients, were of childhood onset and caused by weakly virulent Salmonella or Mycobacteria (Bacille Calmette-Guérin -BCG- and environmental Mycobacteria). Three patients had clinical tuberculosis, one of whom also had salmonellosis. Unlike salmonellosis, mycobacterial infections did not recur. BCG inoculation and BCG disease were both effective against subsequent environmental mycobacteriosis, but not against salmonellosis. Excluding the probands, seven of the 12 affected siblings have remained free of case-definition opportunistic infection. Finally, only five deaths occurred in childhood, and the remaining 36 patients are alive and well. Thus, a diagnosis of IL-12Rβ1 deficiency should be considered in children with opportunistic mycobacteriosis or salmonellosis; healthy siblings of probands and selected cases of tuberculosis should also be investigated. The overall prognosis is good due to broad resistance to infection and the low penetrance and favorable outcome of infections. Unexpectedly, human IL-12 is redundant in protective immunity against most microorganisms other than Mycobacteria and Salmonella. Moreover, IL-12 is redundant for primary immunity to Mycobacteria and Salmonella in many individuals and for secondary immunity to Mycobacteria but not to Salmonella in most.